Memantine Hydrochloride

證據等級: L5

預測適應症: 0 個

---

目錄

1. Memantine Hydrochloride
2. Memantine Hydrochloride: Evaluation Report — Insufficient Data for Repurposing Assessment
   1. One-Sentence Summary
   2. Quick Overview
   3. Data Gaps Identified
   4. Background on Memantine Hydrochloride
   5. Safety Considerations
   6. Conclusion and Next Steps
   7. Disclaimer

---

## 藥師評估報告

Memantine Hydrochloride: Evaluation Report — Insufficient Data for Repurposing Assessment

One-Sentence Summary

Memantine hydrochloride is an NMDA receptor antagonist widely approved internationally for moderate-to-severe Alzheimer’s disease. The current Evidence Pack contains no TxGNN-predicted new indications, and all critical data fields — regulatory licence records, mechanism of action, and safety warnings — are absent or flagged as data gaps. This report documents the identified gaps and outlines the remediation steps required before a repurposing assessment can proceed.

---

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	No predictions available
TxGNN Prediction Score	N/A
Evidence Level	N/A — insufficient data to classify
Canada Market Status	Not Marketed (0 DINs on record)
Number of DINs	0
Recommended Decision	Hold

---

Data Gaps Identified

Two blocking/high-severity gaps were flagged during Evidence Pack assembly and prevent standard evaluation from proceeding:

Gap ID	Category	Missing Item	Severity	Impact	Remediation Source
DG001	Drug Level	Package insert warnings & contraindications	Blocking	Cannot complete S1 safety pre-screening	Health Canada DPD / product monograph PDF
DG002	Drug Level	Mechanism of action (MOA)	High	Cannot perform mechanistic relevance analysis	DrugBank API (query INN: memantine)

---

Background on Memantine Hydrochloride

The following is based on published pharmaceutical references, as the Evidence Pack contains no MOA or indication data.

Memantine hydrochloride is a low-to-moderate-affinity, uncompetitive NMDA (N-methyl-D-aspartate) receptor antagonist. By selectively blocking pathological tonic NMDA receptor activation — driven by excess glutamate in neurodegeneration — while preserving physiological synaptic transmission, it reduces excitotoxic neuronal damage. It is approved in the United States (Namenda®), Europe (Ebixa® / Axura®), and many other markets for moderate-to-severe Alzheimer’s disease.

The Evidence Pack records 0 Canadian DINs with a market status of “not marketed.” This likely reflects a drug-name matching or data-loading error in the ingestion pipeline rather than a genuine absence from the Canadian market, and should be verified against the Health Canada Drug Product Database (DPD) before drawing any regulatory conclusions.

---

Safety Considerations

All safety fields in the Evidence Pack are marked as data gaps. Until DG001 is resolved, please refer to the product monograph and Health Canada–approved labelling for the following, which are known from published sources to be relevant to this drug class:

• Contraindications: Severe renal impairment; known hypersensitivity
• Key Warnings: Seizure history; hepatic impairment; conditions that raise urinary pH (e.g., carbonic anhydrase inhibitors, sodium bicarbonate)
• Drug Interactions: Co-administration with other NMDA antagonists (amantadine, dextromethorphan, ketamine) should be avoided; caution with L-DOPA, dopaminergic agonists, anticholinergic agents

These items are cited for awareness only and must be confirmed against the actual Health Canada–approved labelling before any safety assessment is documented.

---

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Memantine Hydrochloride is missing all TxGNN prediction outputs, regulatory licence records, and safety data. No repurposing evaluation — mechanistic, clinical, or safety — can be completed in its current state.

To proceed, the following is needed:

1. Resolve DG001 (Blocking): Download and parse the Health Canada product monograph (DPD) or manufacturer package insert to extract warnings, contraindications, and adverse reactions; this gate must be cleared before S1 safety pre-screening.
2. Resolve DG002 (High): Query the DrugBank API using the INN “memantine” to obtain the DrugBank ID, MOA, pharmacodynamics, and drug category; the current drugbank_id field is null despite the query log reporting a successful DrugBank lookup — this discrepancy should be investigated.
3. Verify Canadian DIN records: Cross-check Health Canada DPD directly for all memantine HCl product entries; the 0-DIN result is inconsistent with known international market availability and suggests a pipeline matching issue.
4. Re-run TxGNN pipeline: Determine whether the empty predicted_indications array results from a model execution failure or a missing DrugBank ID prerequisite; re-run after populating the required drug identifiers.
5. Re-generate Evidence Pack: Once gaps are resolved and TxGNN predictions are available, re-run the full evidence collection pipeline (ClinicalTrials.gov, PubMed, ICTRP) against the top-ranked predicted indication(s) to produce a complete, assessable Evidence Pack.

   Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---